EE159 Cost Effectiveness of Pembrolizumab Combined with Chemotherapy Vs. Chemotherapy As First-Line Treatment for Metastatic TNBC That Expresses PD-L1 in the United States
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.408
https://www.valueinhealthjournal.com/article/S1098-3015(22)00609-X/fulltext
Title :
EE159 Cost Effectiveness of Pembrolizumab Combined with Chemotherapy Vs. Chemotherapy As First-Line Treatment for Metastatic TNBC That Expresses PD-L1 in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00609-X&doi=10.1016/j.jval.2022.04.408
First page :
Section Title :
Open access? :
No
Section Order :
10358